Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma

[featured_image]
Download is available until [expire_date]
  • Version
  • Download 2
  • File Size 561.65 KB
  • File Count 1
  • Create Date 01/10/2022
  • Last Updated 01/10/2022

Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma

© 2022, PPHI